All data are based on the daily closing price as of May 7, 2025
o

OBI Pharma

4174.TWO
1.30 USD
0.01
+0.78%

Overview

Last close
1.30 usd
Market cap
342.89M usd
52 week high
2.84 usd
52 week low
1.14 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
158.1718
Price/Book Value
2.7402
Enterprise Value
258.16M usd
EV/Revenue
124.8815
EV/EBITDA
-12.3211

Key financials

Revenue TTM
2.07M usd
Gross Profit TTM
-2.52M usd
EBITDA TTM
-72.89M usd
Earnings per Share
-0.33 usd
Dividend
N/A usd
Total assets
172.44M usd
Net debt
N/A usd

About

OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; BsADC which is in discovery stage for the treatment of solid tumors. It also engages in investing and trading; and manufacture and wholesale of western pharmaceuticals, as well as research and development of biotechnology. OBI Pharma, Inc. was founded in 2002 and is headquartered in Taipei, Taiwan.
  • Symbol
    4174.TWO
  • Exchange
    TWO
  • Isin
    TW0004174008
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Ming-Tien Lai
  • Headquarter
    Taipei
  • Web site
    https://www.obipharma.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top